Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Shunda Du
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
72High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07639138CT.gov Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC | — | Recruiting | — | — | — |
NCT07363356CT.gov Drug Sensitivity Testing-Based Tumor Organoids to Guide Adjuvant Therapy After Hepatectomy for Primary Liver Cancer | — | Not Yet Recruiting | — | — | — |
NCT07351513CT.gov A Phase II Trial of Organoid Drug Sensitivity Testing to Guide Therapy in Unresectable Hepatocellular Carcinoma | — | Not Yet Recruiting | — | — | — |
NCT05669339CT.gov AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06309485CT.gov Phase 2 Study of WGI-0301 for Advanced HCC | — | Recruiting | — | — | — |
NCT05822752CT.gov Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC) | — | Active Not Recruiting | — | — | — |
NCT05873244CT.gov CXD101 in Immunotherapy-related Liver Cancer | — | Active Not Recruiting | — | — | — |
NCT05033522CT.gov Immunotherapy for Advanced Liver Cancer | — | Suspended | — | — | — |
NCT06527495CT.gov Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT06030895CT.gov Sorafenib In Egyptian Patients With Hepatocellular Carcinoma. | — | Completed | — | — | — |
Show 219 more trialsShow fewer
NCT04465734CT.gov A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC | — | Withdrawn | — | — | — |
NCT05468359CT.gov Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients | — | Recruiting | — | — | — |
NCT05117957CT.gov Efficacy and Safety of Sorafenib in Previously Treated Advanced Hepatocellular Carcinoma: SOPT Study | — | Completed | — | — | — |
NCT05717738CT.gov Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT04710641CT.gov Radomised Phase II Study of MTL-CEBPA Plus Sorafenib or Sorafenib Alone | — | Completed | — | — | — |
NCT05113290CT.gov Effect and Safety of Recombinant Human Adenovirus Type 5 in Advanced HCC With Stable Disease After Sorafenib Treatment | — | Unknown | — | — | — |
NCT04985136CT.gov A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) | — | Terminated | — | — | — |
NCT04992143CT.gov TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC | — | Unknown | — | — | — |
NCT04770896CT.gov A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab | — | Active Not Recruiting | — | — | — |
NCT04763408CT.gov A Study to Evaluate the Safety and Tolerability of Lenvatinib in Participants With Advanced or Unresectable Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT04709380CT.gov Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT | — | Terminated | — | — | — |
NCT04720716CT.gov A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC | — | Completed | — | — | — |
NCT04229355CT.gov DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT05535998CT.gov TACE-HAIC Combined With TKIs and Immunotherapy Versus TACE Alone for Hepatocellular Carcinoma With PVTT | — | Completed | — | — | — |
NCT04560894CT.gov SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT04723004CT.gov Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC | — | Unknown | — | — | — |
NCT04599777CT.gov TACE Combined With Sorafenib and Tislelizumab for Advanced HCC | — | Completed | — | — | — |
NCT04518852CT.gov TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC | — | Completed | — | — | — |
NCT04344158CT.gov A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC) | — | Active Not Recruiting | — | — | — |
NCT05713994CT.gov Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma | — | Recruiting | — | — | — |
NCT04387695CT.gov SBRT+TACE+Sorafenib Vs Sorafenib in the Treatment of uHCC With PVTT | — | Unknown | — | — | — |
NCT04000737CT.gov YIV-906 (Formerly PHY906/KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT04069949CT.gov Sorafenib Plus Toripalimab for Unresectable HCC With Portal Vein Tumor Thrombus | — | Unknown | — | — | — |
NCT04152356CT.gov Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT04135690CT.gov HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial | — | Unknown | — | — | — |
NCT04103398CT.gov TACE Plus Sorafenib Versus TACE Alone for Recurrent Intermediate Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT04039607CT.gov A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT04143191CT.gov Sorafenib Plus TACE Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced HCC | — | Unknown | — | — | — |
NCT03971201CT.gov A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion | — | Unknown | — | — | — |
NCT04127396CT.gov Lenvatinib Plus TACE Versus Sorafenib Plus TACE for HCC With PVTT | — | Unknown | — | — | — |
NCT04926532CT.gov Toripalimab Plus Sorafenib in Patients With Advanced-Stage Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT03764293CT.gov A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC | — | Completed | — | — | — |
NCT05889949CT.gov Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT03965546CT.gov ET 140202 -T Cell Combined With TAE or Sorafenib in the Treatment of Liver Cancer | — | Unknown | — | — | — |
NCT03899428CT.gov Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC | — | Recruiting | — | — | — |
NCT03780634CT.gov HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC | — | Withdrawn | — | — | — |
NCT03606590CT.gov Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA) | — | Completed | — | — | — |
NCT03794440CT.gov A Study to Evaluate the Efficacy and Safety of Sintilimab in Combination With IBI305 (Anti-VEGF Monoclonal Antibody) Compared to Sorafenib as the First-Line Treatment for Advanced Hepatocellular Carcinoma. | — | Unknown | — | — | — |
NCT02436902CT.gov Adjuvant Therapies for Patients With HCC and MVI | — | Unknown | — | — | — |
NCT03644511CT.gov Use of Sorafenib and/or Regorafenib in Liver Cancer (Hepatocellular Carcinoma) Subsequent to Another Systemic First-line Treatment | — | Terminated | — | — | — |
NCT03730675CT.gov Irradiation Stent Placement Plus TACE for HCC and PVTT | — | Unknown | — | — | — |
NCT03812783CT.gov HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC | — | Unknown | — | — | — |
NCT03645980CT.gov DKN-01 Inhibition in Advanced Liver Cancer | — | Unknown | — | — | — |
NCT03812770CT.gov Phase 2 Study of Sorafenib Plus HAIC of FOLFOX vs. Sorafenib Plus HAIC of OXA for Advanced HCC | — | Unknown | — | — | — |
NCT03582618CT.gov CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT03755791CT.gov Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy | — | Active Not Recruiting | — | — | — |
NCT03722498CT.gov Phase Ⅱ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE | — | Withdrawn | — | — | — |
NCT03563170CT.gov QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine | — | Withdrawn | — | — | — |
NCT03533582CT.gov Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery | — | Active Not Recruiting | — | — | — |
NCT03439891CT.gov Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer | — | Completed | — | — | — |
NCT03434379CT.gov A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT03468231CT.gov HAIC of FOLFOX vs. HAIC of OXA for Advanced HCC | — | Unknown | — | — | — |
NCT03412773CT.gov A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT03211416CT.gov Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer | — | Completed | — | — | — |
NCT03298451CT.gov Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma | — | Active Not Recruiting | — | — | — |
NCT03236649CT.gov The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects | — | Terminated | — | — | — |
NCT03017326CT.gov Paediatric Hepatic International Tumour Trial | — | Active Not Recruiting | — | — | — |
NCT03009461CT.gov Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis | — | Completed | — | — | — |
NCT03097848CT.gov Efficacy and Safety of Sorafenib as Adjuvant and Latter Radiofrequency Ablation for Recurrent Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT02988440CT.gov Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | — | Completed | — | — | — |
NCT02989870CT.gov Sorafenib and Bavituximab Plus SBRT in Unresectable Hepatocellular Carcinoma | — | Withdrawn | — | — | — |
NCT03037437CT.gov Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer | — | Completed | — | — | — |
NCT02971696CT.gov Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients. | — | Completed | — | — | — |
NCT02560779CT.gov Trial of TRC105 and Sorafenib in Patients With HCC | — | Completed | — | — | — |
NCT02973204CT.gov Circulating Tumor Cells and Tumor DNA in HCC and NET | — | Completed | — | — | — |
NCT02856126CT.gov HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC | — | Completed | — | — | — |
NCT02575339CT.gov MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT03578874CT.gov SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC | — | Completed | — | — | — |
NCT02908165CT.gov Randomized Phase II Trial of Chemoembolization and Sorafenib | — | Withdrawn | — | — | — |
NCT02867280CT.gov Sorafenib Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection | — | Terminated | — | — | — |
NCT02774187CT.gov Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC | — | Completed | — | — | — |
NCT05121571CT.gov The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study | — | Completed | — | — | — |
NCT02748304CT.gov Sorafenib Combined With Aspirin to Prevent the Recurrence in High-risk Patients With Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT02645981CT.gov Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT02716766CT.gov Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT02716012CT.gov First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer | — | Unknown | — | — | — |
NCT02642913CT.gov Study of Enzalutamide With and Without Sorafenib in Advanced Hepatocellular Carcinoma Patients | — | Completed | — | — | — |
NCT02672488CT.gov Metformin Plus Sorafenib for Advanced HCC | — | Unknown | — | — | — |
NCT02460991CT.gov A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT02562755CT.gov Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone | — | Completed | — | — | — |
NCT02529761CT.gov TACE With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT02504983CT.gov Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE in Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT02537158CT.gov Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection | — | Unknown | — | — | — |
NCT02129322CT.gov Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1 | — | Withdrawn | — | — | — |
NCT02961998CT.gov Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome, a Single Center, Randomized Controlled Clinical Trail | — | Completed | — | — | — |
NCT04553458CT.gov Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT02423239CT.gov A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours | — | Unknown | — | — | — |
NCT02354898CT.gov A Study of BBI503 in Advanced Solid Tumors, or BBI503/ Sorafenib in Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT02292173CT.gov Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer | — | Completed | — | — | — |
NCT02358395CT.gov A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT02143401CT.gov Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors | — | Completed | — | — | — |
NCT02323906CT.gov Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer | — | Terminated | — | — | — |
NCT02425605CT.gov Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT02794337CT.gov TACE vs TACE+SBRT for Unresectable Hepatocellular Cancer | — | Unknown | — | — | — |
NCT02311205CT.gov Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study) | — | Unknown | — | — | — |
NCT02279719CT.gov A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT02227914CT.gov Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | — | Withdrawn | — | — | — |
NCT02220088CT.gov The Efficacy and Safety of Retreatment With TAI for Patients Who Showed TACE-resistant: a Randomized Controlled Trial | — | Terminated | — | — | — |
NCT02240433CT.gov A Study of LY2157299 in Participants With Unresectable Hepatocellular Cancer (HCC) | — | Completed | — | — | — |
NCT02288507CT.gov Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer | — | Withdrawn | — | — | — |
NCT02406508CT.gov Sequential Melphalan for Use With Hepatic Delivery System Treatment Followed by Sorafenib in Patients With Unresectable HCC | — | Withdrawn | — | — | — |
NCT02259647CT.gov Sorafenib Plus Vitamin K1 Versus Sorafenib in Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT02178358CT.gov A Study of LY2157299 in Participants With Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT04051853CT.gov Sorafenib PK in Patients With Advanced HCC and Child-Pugh B | — | Terminated | — | — | — |
NCT01887717CT.gov Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein | — | Terminated | — | — | — |
NCT01988493CT.gov Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT02733809CT.gov Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT02069145CT.gov Dose Escalation Study of OMP-54F28 in Combination With Sorafenib in Patients With Hepatocellular Cancer | — | Completed | — | — | — |
NCT02072486CT.gov Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT01933945CT.gov Outcomes of HCC (Hepatocellular Carcinoma) Patients Treated With TACE (Transarterial Chemoembolization) and Early, Not Early or Not at All Followed by Sorafenib | — | Completed | — | — | — |
NCT01915602CT.gov Refametinib in Combination With Sorafenib in RAS Mutant Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT01900002CT.gov Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT01897038CT.gov A Safety, Tolerability, and Pharmacokinetics Study of Onartuzumab as Single Agent or in Combination With Sorafenib in Participants With Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT01906216CT.gov Sorafenib Chemoembolization Evaluation Controlled Trial | — | Completed | — | — | — |
NCT01908322CT.gov Investigating Patient Characteristics of Intermediate Stage Hepatocellular Carcinoma Patients Treated With Nexavar and Their Distribution to Different Treatment Groups as Well as Determining Effectiveness and Safety | — | Completed | — | — | — |
NCT01901692CT.gov Sorafenib vs.TransArterial Chemoembolization Plus RadioTherapy in Hepatocellular Carcinoma With Macrovascular Invasion | — | Completed | — | — | — |
NCT01751763CT.gov Sorafenib for Residue Disease After Resection With Curative Intent | — | Completed | — | — | — |
NCT01839630CT.gov Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China | — | Completed | — | — | — |
NCT01849588CT.gov HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC) | — | Terminated | — | — | — |
NCT02400788CT.gov Resminostat (YHI-1001) in Combination With Sorafenib in Asian Patients With Advanced Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT01840592CT.gov Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib | — | Active Not Recruiting | — | — | — |
NCT01761266CT.gov A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT01775501CT.gov Sorafenib + mFOLFOX for Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT01658878CT.gov An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver Cancer | — | Completed | — | — | — |
NCT01687673CT.gov Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT01754987CT.gov A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective | — | Completed | — | — | — |
NCT01605734CT.gov TACE Combinated With Sorafenib in Treating Patients With Unresectable Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT01480817CT.gov Sorafenib VS TACE in HCC Patients With Portal Vein Invasion | — | Terminated | — | — | — |
NCT01618253CT.gov Radiation Therapy With Sorafenib for TACE-Resistant Hepatocellular Carcinoma | — | Withdrawn | — | — | — |
NCT03518502CT.gov Sorafenib Monotherapy vs. TACE-sorafenib Sequential Therapy for HCC With Metastasis | — | Unknown | — | — | — |
NCT01539681CT.gov Sorafenib in Hepatocellular Carcinoma Clinical Practice in Italy | — | Completed | — | — | — |
NCT01801163CT.gov A Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC) | — | Withdrawn | — | — | — |
NCT01498952CT.gov MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC. | — | Completed | — | — | — |
NCT01539018CT.gov Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE | — | Terminated | — | — | — |
NCT01507064CT.gov Neoadjuvant Sorafenib Therapy Prior to Laser Ablation for Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT01482442CT.gov SorAfenib Versus RADIOEMBOLIZATION in Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT01441388CT.gov A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid Tumors. | — | Withdrawn | — | — | — |
NCT01357486CT.gov Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis | — | Completed | — | — | — |
NCT01271504CT.gov E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT01245582CT.gov Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma Patients | — | Withdrawn | — | — | — |
NCT01232296CT.gov A Study of Dovitinib Versus Sorafenib in Adult Patients With Hepatocellular Carcinoma (HCC) as a First Line Treatment | — | Completed | — | — | — |
NCT01348503CT.gov Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT01335074CT.gov Temsirolimus + Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | — | Withdrawn | — | — | — |
NCT01246986CT.gov A Study of LY2157299 in Participants With Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT01308723CT.gov A Dose-Finding and Exploratory Study of RO5323441 in Combination With Sorafenib in Patients With Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT01306058CT.gov Sorafenib and TRC105 in Hepatocellular Cancer | — | Completed | — | — | — |
NCT01258608CT.gov Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT01264705CT.gov Study of Bavituximab and Sorafenib In Patients With Advanced Liver Cancer | — | Completed | — | — | — |
NCT01409499CT.gov Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT01204177CT.gov Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer. | — | Completed | — | — | — |
NCT01265576CT.gov Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC) | — | Unknown | — | — | — |
NCT01217034CT.gov Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib | — | Unknown | — | — | — |
NCT01214343CT.gov Comparing Efficacy of Sorafenib Versus Sorafenib in Combination With Low-dose FP in Patients With Advanced HCC | — | Unknown | — | — | — |
NCT01259193CT.gov Clinical Study of Sorafenib and Zoledronic Acid to Treat Advanced HCC | — | Unknown | — | — | — |
NCT01141478CT.gov Proton Radiotherapy Plus Sorafenib Versus Sorafenib for Patients With HCC Exceeding San Francisco Criteria | — | Terminated | — | — | — |
NCT01098760CT.gov Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients | — | Completed | — | — | — |
NCT01033240CT.gov CS1008- in Combination With Sorafenib Compared to Sorafenib Alone in Subjects With Advanced Liver Cancer | — | Completed | — | — | — |
NCT01135056CT.gov Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC) | — | Unknown | — | — | — |
NCT01903694CT.gov Randomized Trial Sorafenib-Pravastatin Versus Sorafenib Alone for the Palliative Treatment of Child-Pugh A Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT01015833CT.gov Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer | — | Completed | — | — | — |
NCT01009593CT.gov Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC) | — | Terminated | — | — | — |
NCT01008917CT.gov Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT01005875CT.gov Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT01029418CT.gov AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT01004978CT.gov Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | — | Completed | — | — | — |
NCT01004003CT.gov Phase I/II Comparison of Efficacy and Safety of BIBF 1120 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00987935CT.gov A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients | — | Completed | — | — | — |
NCT00999843CT.gov Safety Study of Sorafenib Following Combined Therapy of Radiation and TACE for Liver Cancer | — | Unknown | — | — | — |
NCT01032850CT.gov Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT01042041CT.gov Sorafenib Tosylate and Chemoembolization in Treating Patients With Unresectable Liver Cancer | — | Completed | — | — | — |
NCT01131689CT.gov Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00976170CT.gov Study of GC33 and Sorafenib in Combination in Advanced or Metastatic Liver Cancer (Hepatocellular Carcinoma) | — | Completed | — | — | — |
NCT01012011CT.gov Regulatory Post Marketing Surveillance Study on Nexavar® | — | Completed | — | — | — |
NCT00956436CT.gov Sorafenib With BIIB022 in Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT01171651CT.gov A Study of Recombinant Vaccinia Virus Prior to Sorafenib to Treat Unresectable Primary Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00872014CT.gov A Study of the Effectiveness and Safety of AMG 386 and Sorafenib to Treat Advanced or Inoperable Hepatocellular Cancer | — | Completed | — | — | — |
NCT00943449CT.gov 4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00971126CT.gov Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC) | — | Terminated | — | — | — |
NCT00933816CT.gov Study of Sorafenib In Combination With Low-dose 5-fluorouracil/Cisplatin (FP) Intraarterial Infusion Chemotherapy | — | Completed | — | — | — |
NCT00813293CT.gov Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer | — | Completed | — | — | — |
NCT01170104CT.gov Trial of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib for Locally Advanced Hepatocellular Carcinoma (HCC) | — | Unknown | — | — | — |
NCT00901901CT.gov Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00906373CT.gov A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver | — | Completed | — | — | — |
NCT00858871CT.gov First Line Hepato Cellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT01411436CT.gov Nexavar Post-marketing Surveillance for Hepatocellular Carcinoma in Japan | — | Completed | — | — | — |
NCT00997022CT.gov Trial of Sorafenib in Hepatocellular Cancer (HCC) Transplant Patients | — | Completed | — | — | — |
NCT00863746CT.gov A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC). | — | Completed | — | — | — |
NCT00882869CT.gov XIAP Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT00855218CT.gov A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC). | — | Completed | — | — | — |
NCT00862082CT.gov Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) | — | Terminated | — | — | — |
NCT00808145CT.gov Study of Sorafenib, Gemcitabine, and Cisplatin in Advanced Hepatocellular Carcinoma (HCC) | — | Withdrawn | — | — | — |
NCT00846131CT.gov Y-90 Alone or With Sorafenib for Pre-Transplant Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00844883CT.gov Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00823290CT.gov Sorafenib and LBH589 in Hepatocellular Carcinoma (HCC) | — | Terminated | — | — | — |
NCT00892658CT.gov Sorafenib-RT in Treating Hepatocellular Carcinoma (SHEP) | — | Completed | — | — | — |
NCT00812175CT.gov Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib | — | Completed | — | — | — |
NCT00828594CT.gov Global Study Looking at the Combination of RAD001 and Sorafenib to Treat Patients With Advanced Hepatocellular Carcinoma | — | Terminated | — | — | — |
NCT00791544CT.gov Dose Finding Study of AVE1642 in Patients With Advanced or Metastatic Liver Carcinoma | — | Terminated | — | — | — |
NCT00768937CT.gov Sorafenib and Transarterial Chemoembolization for Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00844688CT.gov Study of Sorafenib and Gemcitabine in Advanced Hepatocellular Carcinoma (HCC) | — | Unknown | — | — | — |
NCT00692770CT.gov Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM) | — | Completed | — | — | — |
NCT00699374CT.gov Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable Liver Cancer | — | Terminated | — | — | — |
NCT00712855CT.gov A Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00712790CT.gov Study of SIR-Spheres Plus Sorafenib as 1st Line Treatment for Non-resectable Primary Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT00792350CT.gov INSIGHT - Post Marketing Surveillance | — | Completed | — | — | — |
NCT00703365CT.gov Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT00576056CT.gov Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC | — | Terminated | — | — | — |
NCT00618384CT.gov TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC) | — | Terminated | — | — | — |
NCT00752063CT.gov Sorafenib With Capecitabine and Oxaliplatin for Advanced or Metastatic Hepatocellular Carcinoma | — | Unknown | — | — | — |
NCT00478374CT.gov Sorafenib With TACE to Treat Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00464919CT.gov Sorafenib Plus Tegafur/Uracil (UFUR®) for Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT00490685CT.gov Dose Escalation of Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT00619541CT.gov Study of Sorafenib and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma (HCC) | — | Completed | — | — | — |
NCT00494299CT.gov Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE) | — | Completed | — | — | — |
NCT00492752CT.gov A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00108953CT.gov A Research Study to Treat Patients With Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00105443CT.gov A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00044512CT.gov A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma | — | Completed | — | — | — |
NCT00941863CT.gov Study to Determine the Safety, Maximum Tolerated Dose, Pharmacokinetics of Sorafenib (BAY43-9006) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Hepatocellular Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Sorafenib (this asset) | Shunda Du | Approved | BB · 69 |
| Adefovir | Bukwang Pharmaceutical | P4 | BBB |
| Huaier Granule | Tongji Hospital | P4 | BBB |
| Fluorouracilum | Li Qiang | P4 | BBB |
| Oxaliplatin | Li Qiang | P4 | BBB |
| Theprubicin | RWTH Aachen University | P4 | BB |
| Adriamycin | VA Office of Research and Development | P4 | BB |
| nrt6003 | Second Affiliated Hospital of Guangzhou Medical University | P3 | BB |
| Epirubicin | Fudan University | P4 | BB |
+42 more in the Hepatocellular Carcinoma cohort
Other indications for Sorafenib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P4 | BBB · 79 |
| Portal Vein Thrombosis | — | P4 | BBB · 74 |
| Adult Hepatocellular Carcinoma | — | P3 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Sorafenib in Hepatocellular Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/sorafenib-hepatocellular-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →